Efinopegdutide (MK‑6024): Dual GLP‑1/Glucagon Peptide for Metabolic Liver Disease
Efinopegdutide (MK‑6024) is a dual GLP‑1/glucagon receptor agonist under investigation for treating metabolic-associated fatty liver disease (MAFLD) and related metabolic disorders. Developed by Merck, this synthetic, PEGylated peptide is engineered to improve liver fat reduction, glucose...